Literature DB >> 15625120

Normal and oncogenic forms of the receptor tyrosine kinase kit.

Johan Lennartsson1, Tanya Jelacic, Diana Linnekin, R Shivakrupa.   

Abstract

Kit is a receptor tyrosine kinase (RTK) that binds stem cell factor. This receptor ligand combination is important for normal hematopoiesis, as well as pigmentation, gut function, and reproduction. Structurally, Kit has both an extracellular and intracellular region. Theintra-cellular region is comprised of a juxtamembrane domain (JMD), a kinase domain, a kinase insert, and a carboxyl tail. Inappropriate expression or activation of Kit is associated with a variety of diseases in humans. Activating mutations in Kit have been identified primarily in the JMD and the second part of the kinase domain and have been associated with gastrointestinal stromal cell tumors and mastocytosis, respectively. There are also reports of activating mutations in some forms of germ cell tumors and core binding factor leukemias. Since the cloning of the Kit ligand in the early 1990s, there has been an explosion of information relating to the mechanism of action of normal forms of Kit as well as activated mutants. This is important because understanding this RTK at the biochemical level could assist in the development of therapeutics to treat primary and secondary defects in the tissues that require Kit. Furthermore, understanding the mechanisms mediating transformation of cells by activated Kit mutants will help in the design of interventions for human disease associated with these mutations. The objective of this review is to summarize what is known about normal and oncogenic forms of Kit. We will place particular emphasis on recent developments in understanding the mechanisms of action of normal and activated forms of this RTK and its association with human disease, particularly in hematopoietic cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15625120     DOI: 10.1634/stemcells.2004-0117

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  87 in total

Review 1.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

2.  Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Authors:  Heidi J Nick; Hyung-Gyoon Kim; Chia-Wei Chang; Kevin W Harris; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

Review 3.  Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics.

Authors:  Edwin Li; Kalina Hristova
Journal:  Cell Adh Migr       Date:  2010-04-23       Impact factor: 3.405

Review 4.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

Review 5.  Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review).

Authors:  Xi Quan; Jianchuan Deng
Journal:  Mol Clin Oncol       Date:  2020-05-25

6.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

Review 7.  Cancer and stem cell signaling: a guide to preventive and therapeutic strategies for cancer stem cells.

Authors:  S Sell
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 5.739

Review 8.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

9.  Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.

Authors:  Jing Gao; Ye Tian; Jian Li; Naiping Sun; Jiajia Yuan; Lin Shen
Journal:  Med Oncol       Date:  2013-03-02       Impact factor: 3.064

10.  Characterization of c-kit (CD117) expression in human normal pituitary cells and pituitary adenomas.

Authors:  Stefano La Rosa; Silvia Uccella; Linda Dainese; Silvia Marchet; Claudia Placidi; Davide Vigetti; Carlo Capella
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.